- C.R. Bard (NYSE:BCR) Q3 results ($M): Total Revenues: 941.9 (+8.8%); Vascular: 258.1 (+3.0%); Urology: 242.1 (+14.0%); Oncology: 258.4 (+8.0%); Surgical Specialties: 158.8 (+13.6%).
- Net Income: 96.4 (+212.1%); Non-GAAP Net Income: 199.5 (+14.2%); EPS: 1.27 (+209.5%); Non-GAAP EPS: 2.64 (+15.8%).
- 2016 Guidance: Revenue Growth: 8 - 9%; Non-GAAP EPS: $10.23 - 10.28.
- Q3 revenues were 1.1% above consensus of $931.7M and non-GAAP EPS was 3.5% above consensus of $2.55.
- Q4 consensus is non-GAAP EPS of $2.74 on revenues of $943.4M.